Newsroom

Industry News

12 Dec

Anavex Upgrades to OTCQX Marketplace

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, today announces that the Company is now trading on the OTCQX marketplace under the Company’s...

Read more

12 Dec

Staffing 360 Solutions Releases Updated Investor Presentation

Presentation Provides an Overview of the Company’s Organic Growth Initiatives and Selective M&A Strategy Staffing 360 Solutions, Inc. (OTCQB: STAF), a public company executing a global buy-and-build strategy through the acquisition of domestic and international staffing organizations with operations in the US and Europe, announced today the publication of...

Read more

11 Dec

PetLife Announces Positive Developments in Special Letter to Shareholders

PetLife Pharmaceuticals, Inc. (PTLF), a developer of new generation of high potency veterinary cancer medications and nutraceuticals for pets, today issued the following Special Letter to Shareholders: Dear Shareholder: PetLife (PTLF) is continuing to make significant strides towards developing the next generation of cancer medications for pets. We are...

Read more

11 Dec

Unilife Hires Intel Marketing Executive Kevin Sellers as Senior Vice President of Marketing and Communications

Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced the appointment of Kevin Sellers, a veteran marketing and communications executive at Intel Corporation, to the post of Senior Vice President, Marketing and Communications.  Sellers will report to Unilife Chairman and CEO Alan...

Read more

11 Dec

Healthcare Sector Movers: Keryx Biopharmaceuticals Inc. (KERX), ACADIA Pharmaceuticals Inc. (ACAD), Smith & Nephew plc (SNN), Stryker Corporation (SYK), Agilent Technologies Inc. (A)

Keryx Biopharmaceuticals Inc. (KERX) has moved with a change from open of 1.51% at mid-day today with a volume of 725,028 shares.  Keryx Biopharmaceuticals Inc. (KERX) is currently trading at $15.51 with a weekly performance of – 2.65% and a 52 week low of 34.52%.  Keryx Biopharmaceuticals Inc. (KERX)’S...

Read more

11 Dec

United Health Products Announces Current Positive State of Events

Positive Product News Better Positions the Company for Global Growth United Health Products, Inc. (OTCQB: UEEC) today released a corporate summary pertaining to recent Company events. Distribution of the Company’s Products Last week United Health Products attended a series of corporate meetings with AMD-Ritmed and Medicom in Montreal, Canada....

Read more

10 Dec

Celator® Pharmaceuticals Presents Data on CPX-351 at the 56th American Society of Hematology Annual Meeting

Celator Pharmaceuticals, Inc. (CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the presentation of data on its lead product candidate, CPX-351 (cytarabine:daunorubicin) Liposome for Injection, at the 56th American Society of Hematology (ASH) Annual...

Read more

9 Dec

Actinium’s Scientific Advisory Board Endorses and Supports the Iomab-B Phase 3 Clinical Trial Development Program

Experts in Leukemia and Bone Marrow Transplant Prepare for Upcoming Pivotal Trial of Actinium’s Iomab-B With the Potential to Change the Way Relapsed and Refractory Acute Myeloid Leukemia (AML) in Older Patients Is Treated Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM)(“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted...

Read more

8 Dec

Experts in Leukemia Treatment Support Ongoing Phase 1/2 Study of Actinium’s Actimab-A, a Low Intensity Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Ages 60 and Older

Actinium’s Clinical Advisory Board Completes Review of Actimab-A Initial Trial Data Underscoring Their Commitment to Actimab’s Development Plan Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM)(“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that their Clinical Advisory Board (CAB)...

Read more

Page 234 of 268« First...102030...232233234235236...240250260...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address